BioPharmaTrend
Latest News
All Topics
  • Artificial Intelligence
  • NeuroTech
  • Premium Content
  • Knowledge Center
Interviews
Companies
  • Company Directory
  • Sponsored Case Studies
  • Create Company Profile
More
  • About Us
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Subscribe
Login/Join

Tissue Selective E3 Ligase-based Degraders

by Chris De Savi  (contributor )   •   May 31, 2022  

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

   Biopharma insight    # Novel Therapeutics   
Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email

The efficacy and selectivity of protein degrader drugs depend on their affinity to the target protein but also on the type of E3 ubiquitin ligase (E3) that is recruited to trigger proteasomal degradation. The arsenal of E3s that can be hijacked for targeted protein degradation (TPD) is still largely unexplored. Only about 2% of the more than 600 E3 ligases have been utilized to date. Exploiting additional E3 ligases that are selectively expressed in specific tissues or cell types, can broaden the applicability of TPD as a therapeutic modality.

#advertisement
How BenchSci’s ASCEND Builds a Map for Biomedical Reasoning

There are many drug target classes for which unwanted on-target pharmacology limits clinical application. Understanding E3 tissue expression across both healthy and diseased tissues enables a disease-directed TPD strategy based on all mapped E3 ligases. Using comparative analyses of expression patterns, one can identify selective pairings of E3 ligases with therapeutic targets of interest. Ligandability, Expression profile and Degradative activity (LED) criteria can be used to identify novel E3 ligases to match with clinically validated targets.

Fragment, structural, and virtual screening approaches have been used to identify ligands to a novel  Cullin E3 ligase, which were successfully made into degraders. The co-crystal structure of an initial fragment hit with a  Kd of > 1 mM was solved by X-ray crystallography revealing interactions within the degron binding pocket of this ligase. SBDD allowed improvement in affinity to approximately 30 uM and further cycles of in silico library design and synthesis further improved the potency to nM hits with good physical properties and low molecular weight. Degraders of multiple proteins including BRD4 and STAT3 were discovered using this novel E3 ligase binder.

Continue reading

This content available exclusively for BPT Mebmers

 BPT Membership 

Topics: Novel Therapeutics   

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email
#advertisement
ThermoFisher Scientific: Integrated genetic technologies for cell therapy development
#advertisement
Webinar: AI in Clinical Trials

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
gnews  Google News
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Premium Content
  • BioTech Scout
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Membership
  • Advertise
  • Submit Company
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.